Dysadherin: A Novel Oncogenic Molecular Biomarker in Oesophageal Cancer
Journal Title: Cancer Studies & Molecular Medicine – Open Journal - Year 2017, Vol 3, Issue 2
Abstract
Dysadherin or FXYD5 is a transmembrane glycoprotein, identified for the first time in 2002 by a team of Japanese researchers.1 Although, it is generally accepted that most of its action is derived from the increased maximal velocity (Vmax) of the Na+ -K+ -ATPase that promotes, there are several actions of dysadherin that cannot be attributed to its interaction with the Na+ -K+ -ATPase.2 Dysadherin is a well-described cancer-associated protein and a potential oncogenic molecular target with promising future significances. It has been distinctly shown, in both the cases of in vivo and in vitro studies, that when expressed in malignant tumours, it signifies augmented tumorigenesis with enhanced metastatic potential and haematogenous spread and is thus linked to poor prognosis.3,4 On the contrary, studies based on human cancer cell lines have demonstrated that introduction of small interfering RNA (siRNA) against dysadherin leads to downregulation and subsequent membranous underexpression of dysadherin, instigating accordingly decreased collective and individual cell motility with subsequent inhibition of tumour aggressiveness and metastatic potential.5 Its main interaction in carcinogenesis takes place with E-cadherin (epithelial cadherin); the most important adhesion molecules of the cadherin family. E-cadherin is involved in cancer development in more than 90% of human cancers, as most are carcinomas of epithelial origin. E-cadherin mediates homophilic cell-to-cell adhesion and promotes adherence between neighboring epithelial cells; its decreased cellular expression is hence associated with enhanced disconnection and dispersal of epithelial cells, promoting cell detachment from the primary lesion and consequently exhibiting increased metastatic potential.
Authors and Affiliations
Alexandros Charalabopoulos
Keywords
Related Articles
- EP ID EP551930
- DOI 10.17140/CSMMOJ-3-e005
- Views 132
- Downloads 0
Gastrointestinal Stromal Tumors: Innovation from Diagnosis to Treatment Based on 15 Years of Experience of a Peripheral Hospital in Portugal
Aim: To investigate fifteen years of experience, in managing GISTs, according to best clinical practice, on a peripheral Portuguese Hospital. Define the behavior of GIST’s and the association between the histological, im...
Dosimetric Characterization of an Abscopal Response in a Patient With Oligometastatic Melanoma Undergoing Concurrent Treatment With Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)
Recently, preclinical and clinical evidence has shown that a synergy may exist between radiation and immune check-point therapies such as pembrolizumab. Radiation has been shown to activate the immune system, and in comb...
Neurofibromatosis Type I and Multiple Gastrointestinal Stromal Tumors: A Unique Identity
Von Recklinghausen’s disease (VRD) is a genetic disorder characterized by the growth of multiple noncancerous tumors of nerves and skin (neurofibromas) and areas of hypo or hyperpigmentation of the skin. It is also known...
The Proportion of ALDEFLUOR-Positive Cancer Stem Cells Changes with Cell Culture Density Due to the Expression of Different ALDH Isoforms
A significant number of discrepancies exist within the literature regarding ALDEFLUOR-positive stem cell populations in cell lines. We hypothesized that these inconsistencies resulted from differences in culture conditio...
Boosting Response: The Impact of Immune Checkpoint Inhibitors on Radiation Treatment Schedules
The recent FDA approvals of immunomodulatory drugs such as Nivoluvamab (Opdivo), Pembrolizumab (Keytruda) and Ipilimumab (Yervoy) for treatment of Non-small cell lung cancer (NSCLC) and melanoma have renewed interest in...